- Current report filing (8-K)
September 20 2012 - 7:03AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The
Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): September 20, 2012
SUNESIS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-51531
|
|
94-3295878
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
395 Oyster Point Boulevard, Suite 400
South San Francisco, California
|
|
94080
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (650) 266-3500
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below
if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 8.01. Other Events.
On September 20, 2012, we issued a press release announcing the closing of two previously disclosed financings: (1) a royalty
financing arrangement with Royalty Pharma and (2) the second tranche closing of a $25.0 million loan facility with a syndicate of lenders led by Oxford Finance LLC with Silicon Valley Bank and Horizon Technology Finance Corporation. A copy of
the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.
Item 9.01. Financial Statements and
Exhibits.
(d)
Exhibits
.
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release, dated September 20, 2012, entitled Sunesis Pharmaceuticals Announces Closing of $40 Million in Previously Announced Royalty and Debt
Financings
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
SUNESIS PHARMACEUTICALS, INC.
|
|
|
Dated: September 20, 2012
|
|
|
|
|
|
|
|
By:
|
|
/s/ Eric H. Bjerkholt
|
|
|
|
|
|
|
|
|
|
Eric H. Bjerkholt
|
|
|
|
|
Executive Vice President, Corporate Development and
Finance, Chief Financial Officer and Corporate Secretary
|
EXHIBIT INDEX
|
|
|
Exhibit No.
|
|
Description
|
|
|
99.1
|
|
Press Release, dated September 20, 2012, entitled Sunesis Pharmaceuticals Announces Closing of $40 Million in Previously Announced Royalty and Debt
Financings
|
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Jul 2024 to Aug 2024
Sunesis Pharmaceuticals (NASDAQ:SNSS)
Historical Stock Chart
From Aug 2023 to Aug 2024
Real-Time news about Sunesis Pharmaceuticals Inc (NASDAQ): 0 recent articles
More News Articles